{"id":"W2147663823","doi":"10.1093/annonc/mdq651","title":"Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"U.S. Food and Drug Administration; Onyx Pharmaceuticals; Canadian Centre for Applied Research in Cancer Control; Bayer HealthCare; Bayer","keywords":"Sorafenib; Medicine; Renal cell carcinoma; Internal medicine; Rash; Oncology; Expanded access; Population; Adverse effect; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Clinical trial; Hepatocellular carcinoma; Surgery; Phases of clinical research; Chemotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003419846,0.0002823358,0.0009094832,0.000194415,0.0001801914,0.00001178912,0.001305924,0.00008502821,0.00004214782],"category_scores_gemma":[0.000266942,0.0002033568,0.000105525,0.0004398627,0.0002060034,0.00019187,0.002087273,0.0006496689,0.00001039715],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009498175,"about_ca_system_score_gemma":0.000292302,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005231015,"about_ca_topic_score_gemma":0.004246558,"domain_scores_codex":[0.9944338,0.003352372,0.000979247,0.0004067316,0.0003722445,0.0004556117],"domain_scores_gemma":[0.9972175,0.0002798914,0.0007565992,0.00122476,0.0003803974,0.0001407943],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01984713,0.1115505,0.765044,0.0001883994,0.0003080942,0.002087077,0.07452385,0.000006873016,0.007598573,0.00001708158,0.003358903,0.01546953],"study_design_scores_gemma":[0.04250684,0.0280663,0.8915161,0.00008129745,0.0001816986,0.00002267642,0.02022974,0.000003461519,0.01675588,0.0000399199,0.00043953,0.0001565918],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9530324,0.00008229574,9.019961e-7,0.0003631231,0.0001005386,0.002571805,0.00006924492,0.00001497396,0.04376467],"genre_scores_gemma":[0.9988343,0.00001559975,0.0001760563,0.000449956,0.00002727996,0.00006249124,0.00002138173,0.00003247473,0.0003804458],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1264721,"threshold_uncertainty_score":0.8292648,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3243979502389615,"score_gpt":0.4237045269783182,"score_spread":0.09930657673935667,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}